CN Patent

CN105263484B — 包含二甲双胍和二氢槲皮素的药物组合及其用于治疗癌症的用途

Assigned to Institute Of Nutrition · Expires 2018-08-03 · 8y expired

What this patent protects

本发明提供了一种能够降低二甲双胍或其药学上可接受的盐的副作用并用作抗恶性肿瘤剂的新型药剂，其中组合了二甲双胍或其药学上可接受的盐和二氢槲皮素或其药学上可接受的盐。

USPTO Abstract

本发明提供了一种能够降低二甲双胍或其药学上可接受的盐的副作用并用作抗恶性肿瘤剂的新型药剂，其中组合了二甲双胍或其药学上可接受的盐和二氢槲皮素或其药学上可接受的盐。

Drugs covered by this patent

Patent Metadata

Patent number
CN105263484B
Jurisdiction
CN
Classification
—
Expires
2018-08-03
Drug substance claim
No
Drug product claim
No
Assignee
Institute Of Nutrition
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.